Bill Maughan
Stock Analyst at Canaccord Genuity
(0.01)
# 4,403
Out of 4,761 analysts
14
Total ratings
12.5%
Success rate
-38.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $26 | $5.72 | +354.55% | 2 | Aug 13, 2024 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $2.05 | +631.71% | 2 | May 10, 2024 | |
| FATE Fate Therapeutics | Maintains: Buy | $11 → $9 | $1.42 | +533.80% | 1 | May 10, 2024 | |
| IMCR Immunocore Holdings | Maintains: Hold | $63 → $67 | $29.92 | +123.93% | 3 | May 9, 2024 | |
| MRNA Moderna | Maintains: Hold | $91 → $106 | $35.53 | +198.34% | 3 | May 3, 2024 | |
| IPSC Century Therapeutics | Maintains: Buy | $22 → $24 | $0.73 | +3,187.22% | 1 | Mar 15, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $60 | $11.66 | +414.58% | 1 | Feb 21, 2024 | |
| MRUS Merus | Initiates: Buy | $45 | $47.37 | -5.00% | 1 | Nov 2, 2023 |
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Buy
Price Target: $26
Current: $5.72
Upside: +354.55%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.05
Upside: +631.71%
Fate Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $1.42
Upside: +533.80%
Immunocore Holdings
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $29.92
Upside: +123.93%
Moderna
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $35.53
Upside: +198.34%
Century Therapeutics
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $0.73
Upside: +3,187.22%
Bicycle Therapeutics
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $11.66
Upside: +414.58%
Merus
Nov 2, 2023
Initiates: Buy
Price Target: $45
Current: $47.37
Upside: -5.00%